The immune system's response to a latent and ubiquitous virus is harnessed to kill tumors in a small study of humans. The approach overcomes a major barrier to effective tumor immunotherapy—generating a sustained immune response (pages 1264–1270).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pule, M.A. et al. Nat. Med. 14, 1264–1270.
Benninger-Doring, G. et al. Virology 264, 289–297 (1999).
Heslop, H.E. et al. Nat. Med. 2, 551–555 (1996).
Sadelain, M., Riviere, I. & Brentjens, R. Nat. Rev. Cancer 3, 35–45 (2003).
Rossig, C., Bollard, C.M., Nuchtern, J.G., Rooney, C.M. & Brenner, M.K. Blood 99, 2009–2016 (2002).
Park, J.R. et al. Mol. Ther. 15, 825–833 (2007).
Kramer, K. et al. Clin. Cancer Res. 4, 2135–2139 (1998).
Frost, J.D. et al. Cancer 80, 317–333 (1997).
Cheung, N.K. et al. J. Clin. Oncol. 16, 3053–3060 (1998).
Berger, C. et al. J. Clin. Invest. 118, 294–305 (2008).
Krause, A. et al. J. Exp. Med. 188, 619–626 (1998).
Maher, J., Brentjens, R.J., Gunset, G., Riviere, I. & Sadelain, M. Nat. Biotechnol. 20, 70–75 (2002).
Stephan, M.T. et al. Nat. Med. 13, 1440–1449 (2007).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
O'Reilly, R. Epstein-Barr virus sustains tumor killers. Nat Med 14, 1148–1150 (2008). https://doi.org/10.1038/nm1108-1148
Issue Date:
DOI: https://doi.org/10.1038/nm1108-1148
This article is cited by
-
Immunotherapy for EBV-associated malignancies
International Journal of Hematology (2011)
-
A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells
Biomedical Microdevices (2010)
